NASDAQ:AVDL Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free AVDL Stock Alerts $18.18 -0.44 (-2.36%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$17.83▼$18.7750-Day Range$12.55▼$18.8252-Week Range$9.50▼$19.09Volume1.50 million shsAverage Volume1.19 million shsMarket Capitalization$1.65 billionP/E RatioN/ADividend YieldN/APrice Target$23.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Avadel Pharmaceuticals alerts: Email Address Avadel Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside30.2% Upside$23.67 Price TargetShort InterestBearish11.71% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.46) to $0.85 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 starsMedical Sector396th out of 903 stocksPharmaceutical Preparations Industry177th out of 420 stocks 4.5 Analyst's Opinion Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAvadel Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Avadel Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted11.71% of the outstanding shares of Avadel Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently increased by 2.12%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVDL. Previous Next 2.4 News and Social Media Coverage News SentimentAvadel Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Avadel Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for AVDL on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat Follows10 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avadel Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.46) to $0.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -8.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -8.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvadel Pharmaceuticals has a P/B Ratio of 18.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Avadel Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Smallcaps DailyThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySee how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.Click to read About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Read More AVDL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVDL Stock News HeadlinesMay 1, 2024 | globenewswire.comAvadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8April 30, 2024 | americanbankingnews.comAvadel Pharmaceuticals (NASDAQ:AVDL) Share Price Passes Above 200-Day Moving Average of $14.01May 8, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.April 29, 2024 | finance.yahoo.comWall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should KnowApril 25, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday TradingApril 21, 2024 | money.usnews.comAvadel Pharmaceuticals plcApril 16, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (AVDL)April 11, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Is Expected To Breakeven In The Near FutureMay 8, 2024 | The Tomorrow Investor (Ad)The Department of Defense Has a New Drone ContractorThe Department of Defense just granted a major advantage to a small UAV provider. Since 1998, this Nasdaq-listed company has been supplying drones for civilian, enterprise, and military purposes.April 2, 2024 | seekingalpha.comAvadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly RevolutionApril 1, 2024 | globenewswire.comAvadel Pharmaceuticals to Present at the 23rd Annual Needham Healthcare ConferenceMarch 17, 2024 | finance.yahoo.comAVDL Apr 2024 15.000 callMarch 16, 2024 | finance.yahoo.comAVDL Apr 2024 25.000 callMarch 16, 2024 | finance.yahoo.comAVDL Apr 2024 10.000 putMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Avadel Pharmaceuticals Amid Strong Q4 Performance and Promising Growth ProspectsMarch 5, 2024 | seekingalpha.comAvadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation OverhangMarch 5, 2024 | realmoney.thestreet.comAvadel Pharmaceuticals price target raised by $2 at Oppenheimer, here's whyMarch 5, 2024 | msn.comAvadel Pharmaceuticals Analysts Increase Their Forecasts After Q4 ResultsMarch 5, 2024 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Q4 2023 Earnings Call TranscriptMarch 4, 2024 | globenewswire.comAvadel Pharmaceuticals Issues Statement On Patent LitigationMarch 4, 2024 | finanznachrichten.deAvadel Pharmaceuticals plc: Avadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 4, 2024 | globenewswire.comAvadel Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 3, 2024 | finance.yahoo.comAVDL Mar 2024 5.000 putMarch 1, 2024 | seekingalpha.comAvadel Pharmaceuticals Q4 2023 Earnings PreviewMarch 1, 2024 | finance.yahoo.comWith 62% ownership, Avadel Pharmaceuticals plc (NASDAQ:AVDL) boasts of strong institutional backingFebruary 26, 2024 | finance.yahoo.comAvadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 4February 25, 2024 | benzinga.comAvadel Pharmaceuticals Stock (NASDAQ:AVDL) Earnings Dates and Earning CallsSee More Headlines Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2024Today5/07/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AVDL CUSIPN/A CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees154Year Founded2015Price Target and Rating Average Stock Price Target$23.67 High Stock Price Target$29.00 Low Stock Price Target$21.00 Potential Upside/Downside+30.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-160,280,000.00 Net MarginsN/A Pretax Margin-574.96% Return on Equity-198.06% Return on Assets-84.51% Debt Debt-to-Equity RatioN/A Current Ratio3.64 Quick Ratio3.36 Sales & Book Value Annual Sales$27.96 million Price / Sales58.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book18.55Miscellaneous Outstanding Shares90,580,000Free Float86,954,000Market Cap$1.65 billion OptionableOptionable Beta1.61 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Gregory J. Divis Jr. (Age 57)CEO & Director Comp: $985.2kMr. Thomas S. McHugh (Age 59)Senior VP, Principal Financial and Accounting Officer & CFO Comp: $663.14kMr. Richard J. Kim (Age 55)Chief Commercial Officer Comp: $770.95kMr. Jerad G. SeurerGeneral Counsel & Company SecretaryMr. Gregory J. Davis (Age 59)VP of Corporate and Business Development Mr. Mark W. ElrodVice President of SalesMs. Angie WoodsVice President of People & CultureDr. Jordan S. Dubow M.D. (Age 45)Consultant Comp: $727.93kDr. Jason M. VaughnSenior Vice President of Technical OperationsMs. Jennifer Gudeman PharmDSenior Vice President of Medical & Clinical AffairsMore ExecutivesKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNEdgewise TherapeuticsNASDAQ:EWTXTaro Pharmaceutical IndustriesNYSE:TAROZai LabNASDAQ:ZLABHarmony BiosciencesNASDAQ:HRMYView All CompetitorsInsiders & InstitutionsObermeyer Wood Investment Counsel LllpBought 279,494 shares on 5/7/2024Ownership: 0.309%Oppenheimer & Co. Inc.Sold 816 shares on 5/7/2024Ownership: 0.041%Chilton Capital Management LLCBought 3,000 shares on 5/7/2024Ownership: 0.003%Quantbot Technologies LPBought 20,915 shares on 5/6/2024Ownership: 0.023%GSA Capital Partners LLPBought 47,596 shares on 5/3/2024Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions AVDL Stock Analysis - Frequently Asked Questions Should I buy or sell Avadel Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVDL shares. View AVDL analyst ratings or view top-rated stocks. What is Avadel Pharmaceuticals' stock price target for 2024? 6 Wall Street analysts have issued 12-month target prices for Avadel Pharmaceuticals' shares. Their AVDL share price targets range from $21.00 to $29.00. On average, they expect the company's stock price to reach $23.67 in the next year. This suggests a possible upside of 30.2% from the stock's current price. View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts. How have AVDL shares performed in 2024? Avadel Pharmaceuticals' stock was trading at $14.12 at the start of the year. Since then, AVDL shares have increased by 28.8% and is now trading at $18.18. View the best growth stocks for 2024 here. When is Avadel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our AVDL earnings forecast. How can I listen to Avadel Pharmaceuticals' earnings call? Avadel Pharmaceuticals will be holding an earnings conference call on Wednesday, May 8th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals plc (NASDAQ:AVDL) issued its earnings results on Monday, March, 4th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.04. The business earned $19.45 million during the quarter, compared to analysts' expectations of $17.41 million. During the same quarter last year, the firm earned ($0.44) earnings per share. What ETFs hold Avadel Pharmaceuticals' stock? ETFs with the largest weight of Avadel Pharmaceuticals (NASDAQ:AVDL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) and AdvisorShares Dorsey Wright ADR ETF (AADR).Invesco Nasdaq Future Gen 200 ETF (QQQS). What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY). Who are Avadel Pharmaceuticals' major shareholders? Avadel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (4.39%), Wealth Effects LLC (2.50%), Obermeyer Wood Investment Counsel Lllp (0.31%), Schulhoff & Co. Inc. (0.15%), Investors Asset Management of Georgia Inc. GA ADV (0.10%) and Iridian Asset Management LLC CT (0.08%). Insiders that own company stock include Eric J Ende, Geoffrey Michael Glass, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh. View institutional ownership trends. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVDL) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorAI “wealth window” is closing June 25thParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.